Stock Analiz

Entera Bio Ltd. ENTX

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026

$3.11Market cap $542M
Open the interactive analysis →

Entera Bio Ltd. (ENTX) is a healthcare company listed in the US with a market value of about $542M. In fiscal year 2025 it had revenue of $42000 and net income of -$11M, a net margin of -27235.7%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -35% a year, a 5-year average ROIC of -76%.

About Entera Bio

Entera Bio is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. Revenue went from $500000 in 2018 to $42000 in 2025, a decline of about 29.8% a year. It was profitable in 0 of the last 10 years in our data. It spends 14295% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B2.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-2.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-76.8%
Revenue growth (5 yrs, per year)-35.1%
EPS growth (5 yrs, per year)-17.9%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-11099.0%
ROIC (5-yr avg.)-76.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$42000$181000$0$134000$571000$365000$236000$500000——
Net income-$11M-$10M-$9M-$13M-$12M-$11M-$11M-$10M-$11M-$1M
Free cash flow-$7M-$7M-$7M-$13M-$9M-$11M-$9M-$10M-$5M-$3M
EPS (diluted)$-0.07$-0.05$-0.05$-0.08$-0.07$-0.06$-0.06$-0.06$-0.06$-0.01
Net margin-27235.7%-5271.3%—-9754.5%-2134.3%-3072.9%-4574.2%-2060.8%——
ROIC-84.8%-90.7%-65.2%-86.8%-53.2%-111.1%-65.7%-84.8%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $9.75, 214% above the current price; targets range from $9.00 to $11.00; the consensus rating is “Strong buy”; expected EPS is $-0.42 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Entera Bio pay a dividend?

Not currently.

Is Entera Bio a good stock to buy?

We do not give buy or sell advice. Entera Bio scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.